H. Lundbeck A/S Release: Vortioxetine, a New Multimodal Agent in Development for the Treatment of Major Depression, Shows Effects on Cognitive Function in Several Preclinical Animal Models

Published: May 22, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Valby, Denmark, 22 May 2013 - H. Lundbeck A/S (Lundbeck) today announced positive results from four pre-clinical animal studies with (vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other health agencies for the treatment of major depression. In these studies the objective was to further study the pharmacological profile of vortioxetine and the potential effects in models of depressive disorders assessing a variety of cognitive functions, including attention, memory and executive function. These studies were presented at the 2013 American Psychiatric Association Annual Meeting (APA) in San Francisco:

Help employers find you! Check out all the jobs and post your resume.

Back to news